Skip to content
Study details
Enrolling now

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

UNC Lineberger Comprehensive Cancer Center
NCT IDNCT05472792ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

90

Study length

about 9.9 years

Ages

65+

Sex

Female only

Locations

1 site in NC

About this study

Researchers are testing whether accelerated partial breast irradiation (APBI) alone, or endocrine therapy alone, after lumpectomy improves quality of life in older women with low-risk breast cancer. The trial will compare the effects of APBI and endocrine therapy on quality of life and disease control.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive Accelerated Partial Breast Irradiation (APBI)
  • 2.Take tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
PhasePhase 2
Druganastrozole
Routeoral
Primary goalPatient reported outcomes assessed by EORTC QLQ-BR45

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

anastrozole, exemestane, fulvestrant, letrozole (Aromatase inhibitor; prevents estrogen production), tamoxifen (Selective estrogen receptor modulator (SERM); blocks estrogen in breast tissue), toremifene

Drug routes

oral (Oral Tablet), oral, injection

Endpoints

Primary: Patient reported outcomes assessed by EORTC QLQ-BR45, Patient reported outcomes assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30

Secondary: Disease-free survival, Overall survival

Procedures

radiation

Body systems

Oncology